Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Agennix has reported the Phase II results of its oral immunotherapy - talactoferrin to treat cancer and severe sepsis.
Subscribe to our email newsletter
The double-blind, placebo-controlled and randomized trial which enrolled 100 patients was designed to assess the efficacy and safety of the talactoferrin in patients with previously treated non-small cell lung cancer (NSCLC).
The study, conducted in patients with NSCLC for whom one or more prior lines of anti-cancer therapy had failed achieved its primary endpoint of improvement in overall survival.
Supportive results were seen in the secondary endpoints of progression-free survival and disease control rate.
Agennix chief medical officer Rajesh Malik said they look forward to report topline results from their ongoing Phase III Fortis-M registration trial in advanced non-small cell lung cancer in the first half of 2012.